The Motley Fool

Top broker slaps buy rating on Cochlear shares

The Cochlear Limited (ASX: COH) share price has managed to push higher in morning trade despite the market sinking lower.

At the time of writing the hearing solutions company’s shares are up 1.5% to $176.70.

Why is the Cochlear share price pushing higher today?

With no news out of Cochlear this morning, today’s gain is likely to be attributable to a broker note out of Citi.

According to the note, the broker has upgraded Cochlear’s shares to a buy rating from neutral and lifted the price target on them to $198.00.

This price target implies potential upside of approximately 12% for its shares over the next 12 months.

Why is Citi bullish on Cochlear?

The broker has made the move after Cochlear’s share price tumbled lower over the last couple of weeks.

Prior to today, Cochlear’s shares had lost around 12% of their value since February 15. Citi felt that the selling had been overdone, prompting the upgrade.

In addition to this, its analysts now believe that Cochlear will overcome the impact of increased competition in the U.S. from competitors such as Sonova. It expects Cochlear’s implant growth in that market to resume in the second half of FY 2020.

Should you buy Cochlear’s shares?

I agree with Citi and think that Cochlear would be a great investment after its recent share price weakness. Although its first half results were a touch softer than expected, I feel investors ought to focus more on the next decade.

I believe that Cochlear’s long-term outlook is very positive due to the ageing populations tailwind, its high quality existing products, pipeline of exciting products under development, and its global distribution network.

Overall, I believe it would be a great buy and hold option along with fellow healthcare stars CSL Limited (ASX: CSL) and ResMed Inc. (ASX: RMD).

And if you like Cochlear, CSL, and ResMed, then I think you'll love these buy-rated blue chips.

Top 3 ASX Blue Chips To Buy For 2019

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked...

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2019."

Each one pays a fully franked dividend. The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies move – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.